A nice mention for PTI on TheStreet.com in the USA yesterday won't have done any harm to PTI's profile:
"Almost lost in the flurry of late December transactions was the Dec. 8 announcement that AstraZeneca had licensed CytoFab, an experimental treatment for sepsis being developed by Protherics (PTIL:Nasdaq ADR - commentary - research - Cramer's Take), a British biotechnology company.
Sepsis is a dangerous and potentially fatal condition caused by severe infections. AstraZeneca says about one-third of patients with severe sepsis die from organ failure. The company says some 3 million people a year are affected by sepsis.
The only sepsis drug on the market is Xigris from Eli Lilly (LLY:NYSE - commentary - research - Cramer's Take). AstraZeneca plans to start a phase III trial in the U.S. and European Union in 2007.
Excluding royalties, AstraZeneca could pay Protherics about $340 million, including acquiring 4.3% of the company's shares."
Patni Computer Systems stock quotes
Patni Computer Systems stock charts
Follow this thread
